Semaglutide Might Treat Heart Failure Directly

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

Novo Nordisk’s product’s reputation as a wonder drug grows as new data suggest it might be disease-modifying in heart failure.    

Heart made out of red puzzle pieces with one piece missing
• Source: Shutterstock

Novo Nordisk A/S’s metabolic monster, semaglutide, is already under review at the US Food and Drug Administration to add heart failure to its litany of approved indications. Data presented at the weekend will add impetus to the argument for its approval, and intriguingly, the STEP-HFpEF DM study suggests that the GLP-1 agonist could treat heart failure over and above its weight loss effects alone.

Key Takeaways

  • Semaglutide has succeeded in a trial in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes

The study tested semaglutide in 616 patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D